TACSTD2 and neoplasm: As new immunotherapies and targeted therapies are revealed,45,46 our findings suggest value in further investigations into a panel of personalized tumor markers, which may include proteins with therapeutic relevance such as FOLR1, KRT19, KLK6, PARP-1, TROP2, and IFNL1.